TG Therapeutics net loss widens in Q3

TG Therapeutics (TGTX +0.4%) Q3 results: Revenues: $0.04M (unch).

Net loss: ($61.9M) (-82.1%); loss/share: ($0.69) (-60.5%); Quick Assets: $72.5M (+5.2%).

Remaining 2019 and Early 2020 Milestones: Initiate a rolling NDA submission for umbralisib to treat adult patients with previously treated marginal zone lymphoma.

Report top-line PFS results from the Phase 3 UNITY-CLL trial evaluating U2 in patients with frontline and previously treated CLL.

Share results from the Phase 2b UNITY-NHL FL cohort with the FDA to determine potential filing opportunities.

Previously: TG Therapeutics EPS misses by $0.35, revenue in-line (Nov. 12)

https://seekingalpha.com/news/3518071-tg-therapeutics-net-loss-widens-q3